lumiracoxib

Lumiracoxib is a highly selective cyclooxygenase‐2 (COX‐2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID). Structurally, it is distinct from other coxibs and closely related to diclofenac, making it part of the arylalkanoic acid NSAID family. Lumiracoxib inhibits prostaglandin synthesis by selectively blocking the COX‐2 enzyme, resulting in anti-inflammatory and analgesic effects. It was primarily developed for acute and chronic treatment of osteoarthritis symptoms in adults but has also been used for acute pain, dysmenorrhea, rheumatoid arthritis, gout, and other pain states. The drug was originally developed by Novartis and marketed under brand names such as Prexige. Due to concerns over hepatotoxicity—including cases of severe liver injury—lumiracoxib has been withdrawn or its use restricted in many countries but remains available in some regions[1][2][4][5].

Brand names

PrexigeJoicela

Other names

lumiracoxibum2-(2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid2-(2-(2-chloro-6-fluorophenylamino)-5-methylphenyl)acetic acid